Clinical Trial Update: A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating eribulin followed by the AC chemotherapy regimen as preoperative therapy for HER2-negative inflammatory breast cancer; results were pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Inflammatory Breast Cancer

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Doxorubicin (doxorubicin)
• Halaven (eribulin)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Inflammatory Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2022-12-28